Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAvita Medical Ltd

Avita Medical Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
18.285 USD 1.70 ( 10.22%)
Last update at 2026-11-09T15:48:00Z
VOLUME
251273
Market Cap
315.76M

Momentum Score

…

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.71
Low
18.43
High
52 Week Price Range
3.22
Low
11.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avita Medical develops and commercial regenerative skin solutions, commercializing the RECELL Autologous Cell Harvesting system for treatment of burns and other skin wounds. Long-term growth may be supported by broader clinical adoption, additional regulatory clearances and reimbursement, geographic expansion and further clinical data. Investors may find the company attractive because the platform could reduce the need for donor skin grafts and address a sizable unmet wound-care market.
Material risks include regulatory and reimbursement uncertainty, commercial execution and competition in wound care, along with potential need for additional financing to sustain growth.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.59
Dividend Yield
-
Revenue TTM
75.63M
Revenue Per Share
2.52
Gross Profit TTM
61.68M
Debt / Equity
-2.77
ROE
-1746.27%
Net Debt
35.80M
ROCE
693.27%
Diluted EPS TTM
-1.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Income before tax -48.58M -61.79M -35.31M -26.63M -26.63M
Net income -48.59M -61.84M -35.38M -26.66M -26.66M
Selling general administrative 27.37M 33.20M 28.33M 23.33M 23.33M
Selling and marketing expenses 53.14M 58.20M 37.29M 21.91M 21.91M
Gross profit 58.82M 55.16M 42.36M 28.38M 28.38M
Reconciled depreciation 2.35M 1.13M 0.63M 0.57M 0.57M
Ebit -43.57M -56.43M -34.17M -27.50M -26.61M
Ebitda -41.23M -55.30M -33.54M -26.05M -26.05M
Depreciation and amortization 2.35M 1.13M 0.63M 1.46M 0.57M
Operating income -42.53M -56.59M -42.66M -27.50M -27.50M
Other operating expenses 114.14M 120.84M 92.80M 61.93M 61.93M
Interest expense 5.00M 5.36M 1.14M 0.02M 0.02M
Tax provision 0.01M 0.05M 0.07M 0.04M 0.04M
Net interest income -5.00M -5.36M -1.14M -0.02M -0.02M
Income tax expense 0.01M 0.05M 0.07M 0.04M 0.04M
Total revenue 71.61M 64.25M 50.14M 34.42M 34.42M
Total operating expenses 101.35M 111.75M 85.02M 55.88M 55.88M
Cost of revenue 12.79M 9.09M 7.78M 6.04M 6.04M
Total other income expense net -6.04M -5.20M 7.34M 0.88M 0.88M
Net income from continuing ops -48.59M -61.84M -35.38M -26.66M -26.66M
Net income applicable to common shares - - - -26.66M -26.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 56.39M 79.71M 111.64M 98.26M 98.26M
Intangible assets 5.64M 5.57M 0.49M 0.47M 0.47M
Other current assets 1.27M 1.88M 1.43M 2.48M 1.39M
Total liab 73.04M 75.21M 62.58M 13.52M 13.52M
Total stockholder equity -16.65M 4.50M 49.06M 84.74M 84.74M
Other current liab 9.80M 12.96M 8.48M 6.88M 7.08M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -408.40M -359.81M -297.97M -262.59M -262.59M
Other liab - - - 2.52M 2.52M
Other assets - - - 1.36M 0.00M
Cash 10.24M 14.05M 22.12M 18.16M 18.16M
Total current liabilities 62.68M 20.16M 13.20M 10.69M 10.69M
Current deferred revenue - - 0.03M 0.19M 0.19M
Net debt 35.80M 31.93M 20.29M -17.25M -17.25M
Short term debt 43.91M 0.90M 0.90M 0.61M 0.61M
Short long term debt 42.98M - - - -
Short long term debt total 46.05M 45.98M 42.41M 0.92M 0.92M
Other stockholder equity 393.12M 366.25M 348.91M 339.70M 339.70M
Property plant equipment - - - 2.05M 2.05M
Total current assets 35.49M 57.00M 104.01M 87.46M 87.46M
Long term investments - - 0.00M 6.93M 6.93M
Net tangible assets - - - 84.28M 84.28M
Short term investments 7.94M 21.84M 66.94M 61.18M 61.18M
Net receivables 9.11M 11.96M 7.92M 4.96M 4.96M
Long term debt - 42.24M 39.81M - -
Inventory 6.93M 7.27M 5.60M 2.12M 2.12M
Accounts payable 8.96M 6.29M 3.79M 3.00M 3.00M
Accumulated other comprehensive income -1.37M -1.94M -1.89M 7.63M 7.63M
Non currrent assets other 3.73M 3.55M 2.83M 1.36M 1.36M
Non current assets total 20.90M 22.71M 7.63M 10.81M 10.81M
Capital lease obligations 3.06M 3.74M 2.60M 0.92M 0.92M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Investments 14.19M 37.36M 1.61M -19.33M -19.33M
Change to liabilities - - - 0.03M 0.03M
Total cashflows from investing activities 12.45M 37.36M 1.61M -19.33M -19.33M
Net borrowings - 0.00M 38.76M - 0.00M
Total cash from financing activities 14.94M 3.51M 40.37M 0.90M 0.90M
Change to operating activities - - - -0.46M -0.46M
Net income -48.59M -61.84M -35.38M -26.66M -26.66M
Change in cash -3.81M -8.07M 3.95M -37.55M -37.55M
Begin period cash flow 14.05M 22.12M 18.16M 55.71M 55.71M
End period cash flow 10.24M 14.05M 22.12M 18.16M 18.16M
Total cash from operating activities -31.20M -48.94M -38.01M -19.09M -19.09M
Issuance of capital stock 14.79M 0.00M - 0.00M 0.00M
Depreciation 2.04M 1.13M 0.63M 0.57M 0.57M
Other cashflows from investing activities -0.73M -0.16M -0.07M - -0.07M
Change to inventory -0.47M -2.16M -3.69M -0.37M -0.37M
Change to account receivables 3.63M -4.17M -3.30M -0.40M -0.98M
Other cashflows from financing activities 0.80M 3.51M 1.61M 0.90M 0.90M
Change to netincome - - - 7.87M 7.87M
Capital expenditures 1.74M 9.33M 1.45M 0.53M 0.53M
Change in working capital 3.44M -4.68M -6.57M -1.20M -1.20M
Stock based compensation 9.52M 13.50M 8.38M 7.00M 7.00M
Other non cash items 2.40M 2.96M -5.07M 1.21M 1.21M
Free cash flow -32.93M -58.27M -39.46M -19.61M -19.61M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RCEL
Avita Medical Ltd		 1.70
10.22%		 18.29 - 10.29 4.17 11.77 4.66 -6.17
ABT
Abbott Laboratories		 -0.36
0.33%		 109.56 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.14
0.14%		 101.66 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -0.84
0.26%		 325.03 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.56
1.12%		 50.41 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Avita Medical Ltd

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

28159 Avenue Stanford, Valencia, CA, United States, 91355

661 367 9170

https://avitamedical.com

226

Name Title Year Born
Mr. James M. Corbett CEO, Pres & Exec. Director 1958
Mr. Michael Bria Holder MBA Chief Financial Officer 1963
Ms. Kathy M. McGee Chief Operating Officer 1966
Mr. Andrew Quick Chief Technology Officer 1971
Ms. Donna Shiroma Gen. Counsel & Sec. 1962
Ms. Erin Liberto Chief Commercial Officer 1975
Mr. David Fencil VP of Global Operations NA
Ms. Debbie Garner VP of Global Marketing NA
Mr. James M. Corbett CEO, President & Executive Director 1958
Mr. David O'Toole Chief Financial Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…